Literature DB >> 16488076

ARLTS1 variants and risk of colorectal cancer.

Bernd Frank1, Kari Hemminki, Hermann Brenner, Michael Hoffmeister, Jenny Chang-Claude, Barbara Burwinkel.   

Abstract

The Cys148Arg and Trp149Stop variants in the tumour suppressor gene ARLTS1 predispose to familial breast cancer, suggesting that these variants might also contribute to colorectal carcinogenesis. As the first to evaluate the association between Cys148Arg and Trp149Stop and colorectal cancer (CRC) risk, we genotyped 611 cases with CRC (including 77 cases with a first-degree family history) and 539 controls recruited from the German DACHS study. No significant differences in the genotype frequencies of Cys148Arg and Trp149Stop were observed between cases and controls. However, we showed a non-significant increased risk of familial CRC for both variants (OR=1.40 and 1.45), indicating a possible role of ARLTS1 in familial CRC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16488076     DOI: 10.1016/j.canlet.2005.12.006

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  11 in total

1.  ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer.

Authors:  Elif Akisik; Hulya Yazici; Nejat Dalay
Journal:  Mol Biol Rep       Date:  2010-04-01       Impact factor: 2.316

2.  ARLTS1 germline variants and the risk for breast, prostate, and colorectal cancer.

Authors:  Sanna Siltanen; Kirsi Syrjäkoski; Rainer Fagerholm; Tarja Ikonen; Peter Lipman; Jacob Mallott; Kaija Holli; Teuvo L J Tammela; Heikki J Järvinen; Jukka-Pekka Mecklin; Kristiina Aittomäki; Carl Blomqvist; Joan E Bailey-Wilson; Heli Nevanlinna; Lauri A Aaltonen; Johanna Schleutker; Pia Vahteristo
Journal:  Eur J Hum Genet       Date:  2008-03-12       Impact factor: 4.246

3.  Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins.

Authors:  Anna Abulí; Ceres Fernández-Rozadilla; Virginia Alonso-Espinaco; Jenifer Muñoz; Victoria Gonzalo; Xavier Bessa; Dolors González; Joan Clofent; Joaquin Cubiella; Juan D Morillas; Joaquim Rigau; Mercedes Latorre; Fernando Fernández-Bañares; Elena Peña; Sabino Riestra; Artemio Payá; Rodrigo Jover; Rosa M Xicola; Xavier Llor; Luis Carvajal-Carmona; Cristina M Villanueva; Victor Moreno; Josep M Piqué; Angel Carracedo; Antoni Castells; Montserrat Andreu; Clara Ruiz-Ponte; Sergi Castellví-Bel
Journal:  BMC Cancer       Date:  2011-08-05       Impact factor: 4.430

4.  Contribution of ARLTS1 Cys148Arg (T442C) variant with prostate cancer risk and ARLTS1 function in prostate cancer cells.

Authors:  Sanna Siltanen; Tiina Wahlfors; Martin Schindler; Outi R Saramäki; John Patrick Mpindi; Leena Latonen; Robert L Vessella; Teuvo L J Tammela; Olli Kallioniemi; Tapio Visakorpi; Johanna Schleutker
Journal:  PLoS One       Date:  2011-10-20       Impact factor: 3.240

Review 5.  ARLTS1 polymorphism is associated with an increased risk of familial cancer: evidence from a meta-analysis.

Authors:  Yan Jiang; Chen-Yang Zhao; Li-Chun Cheng; Bing Xu; Hui-Yi Lv
Journal:  Hered Cancer Clin Pract       Date:  2017-06-13       Impact factor: 2.857

Review 6.  The Role of ARF Family Proteins and Their Regulators and Effectors in Cancer Progression: A Therapeutic Perspective.

Authors:  Cristina Casalou; Andreia Ferreira; Duarte C Barral
Journal:  Front Cell Dev Biol       Date:  2020-04-21

7.  ARLTS1 polymorphisms and basal cell carcinoma of the skin.

Authors:  Xuchen Li; Andreas Gast; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Kari Hemminki; Rajiv Kumar
Journal:  Hered Cancer Clin Pract       Date:  2007-03-15       Impact factor: 2.857

8.  ARLTS1 and prostate cancer risk--analysis of expression and regulation.

Authors:  Sanna Siltanen; Daniel Fischer; Tommi Rantapero; Virpi Laitinen; John Patrick Mpindi; Olli Kallioniemi; Tiina Wahlfors; Johanna Schleutker
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

9.  ARL11 regulates lipopolysaccharide-stimulated macrophage activation by promoting mitogen-activated protein kinase (MAPK) signaling.

Authors:  Subhash B Arya; Gaurav Kumar; Harmeet Kaur; Amandeep Kaur; Amit Tuli
Journal:  J Biol Chem       Date:  2018-04-04       Impact factor: 5.157

10.  Silencing of ARL14 Gene Induces Lung Adenocarcinoma Cells to a Dormant State.

Authors:  Fei Guo; Dexiao Yuan; Junling Zhang; Hang Zhang; Chen Wang; Lin Zhu; Jianghong Zhang; Yan Pan; Chunlin Shao
Journal:  Front Cell Dev Biol       Date:  2019-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.